Tuberculosis is a first magnitude sanitary problem with several factors that make difficult its eradication, among these are particularly important those derived from the antituberculous therapy: noncompliance and adverse reactions to the drugs used. We have developed a follow-up program for ambulatory patients with antituberculous therapy that includes compliance control and systematical survey or possible adverse reactions. We expose our results after its application to 39 patients with tuberculosis and 24 with tuberculous infection. The compliance level among patients with tuberculous disease was 100% and among those who were receiving chemoprophylaxis 75%, both values much higher than those found in the literature. We detected adverse reactions in 43.6% of the patients with tuberculous treatment and 37.5% of those receiving chemoprophylaxis with isoniazid. Setting up follow-up programs in antituberculous treatments notably helps to improve the compliance and the safety of treatment.